Hubei Jumpcan subsidiary invests 100 million yuan in cash management

Hubei Jumpcan Pharmaceutical announced its wholly-owned subsidiary will engage in cash management by investing 100 million yuan of idle raised funds. The investment is split into two Hangzhou Bank "Tianlibao" structured deposit products: one for 178 days and another for 179 days, both featuring principal-protected floating yields. These products are anticipated to generate an estimated yield range of 0.75% to 2.22%.

The decision was approved during the company’s tenth board of directors' fourteenth meeting, tenth board of supervisors' fourteenth meeting on April 25, 2025, and the 2024 annual shareholders' meeting on May 16, 2025. The total authorized amount for such cash management, including idle raised funds and own capital, is up to 580 million yuan. This strategy aims to improve capital utilization without affecting the progress of the company's investment projects.

As of June 30, 2025, Hubei Jumpcan's asset-liability ratio was 18.85%. The company has committed 550 million yuan to cash management over the past 12 months, with a maximum single-day investment of 600 million yuan. The company emphasizes a low-risk, highly liquid approach to these investments, though it acknowledges potential market volatility due to macroeconomic factors.